Sareum Holdings PLC Notice of AGM, Annual Report and Accounts (0551U)
21 November 2023 - 8:00AM
UK Regulatory
TIDMSAR
RNS Number : 0551U
Sareum Holdings PLC
21 November 2023
Sareum Holdings PLC
("Sareum" or the "Company")
Notice of AGM, Annual Report and Accounts
Cambridge, UK, 21 November 2023 - Sareum Holdings plc (AIM:
SAR), a biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer, today announces that
the Company's Annual General Meeting ("AGM") will be held at
10.00am on 14 December 2023 at 85 Gresham Street, London EC2V
7NQ.
In order to allow shareholders to follow the proceedings of the
AGM without attending in person, the Company will provide access
online via the Investor Meet Company ("IMC") platform. Shareholders
who wish to follow the AGM online should register for the event in
advance by using the following link:
www.investormeetcompany.com/sareum-holdings-plc/register-investor
.
Shareholders are invited to submit questions for the Board to
consider in the Q&A session to be held immediately after the
AGM. Questions can be pre submitted via the IMC Platform up until
9.00am the day before the meeting and can be submitted at any time
during the AGM itself. Shareholders are reminded that following the
AGM online will not constitute attendance at the AGM and therefore
will not be able to vote on the day.
Shareholders intending to vote should do so via the shareholder
portal at www.signalshares.com where details of the procedure are
shown. Alternatively, shareholders may request a paper form of
proxy from our registrars, Link Group.
The notice of AGM, along with a copy of the Company's annual
report and accounts for the year ended 30 June 2023, will be posted
today to those shareholders who requested a hard copy. A copy of
both documents will also be available on the Company's website:
www.sareum.com
-Ends-
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497700
Lauren Williams, Head of Investor Relations ir@sareum.co.uk
Strand Hanson Limited (Nominated Adviser)
James Dance / James Bellman 020 7409 3494
Peel Hunt LLP (Joint Corporate Broker)
James Steel / Patrick Birkholm 020 7418 8900
Hybridan LLP (Joint Corporate Broker)
Claire Noyce
020 3764 2341
ICR Consilium (Financial PR)
Jessica Hodgson / Davide Salvi / Stella
Lempidaki 020 3709 5700
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology
company developing next generation kinase inhibitors for autoimmune
disease and cancer.
The Company is focused on developing next generation small
molecules which modify the activity of the JAK kinase family and
have best-in-class potential. Its lead candidate, SDC-1801,
simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential
treatment for a range of autoimmune diseases and has entered Phase
1a/b clinical development with an initial focus on psoriasis.
Sareum has an economic interest in SRA737, a clinical-stage Chk1
inhibitor which it originally developed in collaboration with
several Cancer Research UK-related organisations. SRA737 has shown
promising safety and efficacy in two Phase 1/2 clinical trials.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a
potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on
the AIM market of the London Stock Exchange, trading under the
ticker SAR. For further information, please visit the Company's
website at www.sareum.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOABMBMTMTITTAJ
(END) Dow Jones Newswires
November 21, 2023 02:00 ET (07:00 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Sareum (LSE:SAR)
Historical Stock Chart
Von Jun 2023 bis Jun 2024